Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection | MicrobiomeTrials← Back to trialsNCT04308278
Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2021-01-22Est. Completion: 2028-08-22
Enrollment target: 88 participants Locations- Private practice of Dr Pieterjan DEBBAUT, Heule, Kortrijk, Belgium
- Private Practice, Aartselaar, Belgium
- Private Practice, Brussels, Belgium
- Private Practice, Ghent, Belgium
- Private practice, Marche-en-Famenne, Belgium
- Cabinet privé, Schoten, Belgium
- Private practice, Stavelot, Belgium
- Private practice, Waregem, Belgium
Other microbiome trials you might be interested in
B Acute Lymphoblastic Leukemia
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemothe…
Birmingham, United StatesEst. completion Dec 1, 2030
EBV InfectionStage II Nasopharyngeal Carcinoma AJCC v7Stage III Nasopharyngeal Carcinoma AJCC v7Stage IVA Nasopharyngeal Carcinoma AJCC v7Stage IVB Nasopharyngeal Carcinoma AJCC v7
There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Ba…
Birmingham, United StatesEst. completion Dec 1, 2026
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating p…
Birmingham, United StatesEst. completion Feb 1, 2027